PL3507303T3 - Przeciwciała CD20 - Google Patents
Przeciwciała CD20Info
- Publication number
- PL3507303T3 PL3507303T3 PL17762244.6T PL17762244T PL3507303T3 PL 3507303 T3 PL3507303 T3 PL 3507303T3 PL 17762244 T PL17762244 T PL 17762244T PL 3507303 T3 PL3507303 T3 PL 3507303T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16186850 | 2016-09-01 | ||
| PCT/NL2017/050581 WO2018044172A1 (en) | 2016-09-01 | 2017-09-01 | Cd20 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3507303T3 true PL3507303T3 (pl) | 2025-12-08 |
Family
ID=56852201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17762244.6T PL3507303T3 (pl) | 2016-09-01 | 2017-09-01 | Przeciwciała CD20 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11414495B2 (pl) |
| EP (1) | EP3507303B1 (pl) |
| JP (1) | JP2019530661A (pl) |
| CN (1) | CN109843925A (pl) |
| AU (1) | AU2017320457A1 (pl) |
| CA (1) | CA3035427A1 (pl) |
| ES (1) | ES3049907T3 (pl) |
| HU (1) | HUE073389T2 (pl) |
| PL (1) | PL3507303T3 (pl) |
| WO (1) | WO2018044172A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113260632A (zh) * | 2018-10-29 | 2021-08-13 | 蒂嘉特克斯公司 | 包含IgA抗体构建体的组合物和方法 |
| CN114096559B (zh) | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| AU2020351205A1 (en) * | 2019-09-19 | 2022-04-14 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| CN1802388B (zh) * | 2003-05-09 | 2011-01-05 | 杜克大学 | Cd20特异抗体及使用它们的方法 |
-
2017
- 2017-09-01 CA CA3035427A patent/CA3035427A1/en not_active Abandoned
- 2017-09-01 AU AU2017320457A patent/AU2017320457A1/en not_active Abandoned
- 2017-09-01 CN CN201780064749.4A patent/CN109843925A/zh active Pending
- 2017-09-01 EP EP17762244.6A patent/EP3507303B1/en active Active
- 2017-09-01 WO PCT/NL2017/050581 patent/WO2018044172A1/en not_active Ceased
- 2017-09-01 ES ES17762244T patent/ES3049907T3/es active Active
- 2017-09-01 JP JP2019511980A patent/JP2019530661A/ja active Pending
- 2017-09-01 PL PL17762244.6T patent/PL3507303T3/pl unknown
- 2017-09-01 HU HUE17762244A patent/HUE073389T2/hu unknown
- 2017-09-01 US US16/329,726 patent/US11414495B2/en active Active
-
2022
- 2022-06-15 US US17/841,326 patent/US20230022731A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3507303B1 (en) | 2025-07-23 |
| EP3507303C0 (en) | 2025-07-23 |
| CN109843925A (zh) | 2019-06-04 |
| HUE073389T2 (hu) | 2026-01-28 |
| ES3049907T3 (en) | 2025-12-18 |
| AU2017320457A1 (en) | 2019-03-28 |
| WO2018044172A1 (en) | 2018-03-08 |
| US20230022731A1 (en) | 2023-01-26 |
| EP3507303A1 (en) | 2019-07-10 |
| JP2019530661A (ja) | 2019-10-24 |
| CA3035427A1 (en) | 2018-03-08 |
| WO2018044172A8 (en) | 2019-03-21 |
| US20190263922A1 (en) | 2019-08-29 |
| US11414495B2 (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201900353B (en) | Anti-pd-l1 antibodies | |
| ZA201900373B (en) | Anti-tim-3 antibodies | |
| IL262295A (en) | Antibodies against pd-l1 | |
| HUS2500024I1 (hu) | ANTI-PD-1 ellenanyagok | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| PL3519437T3 (pl) | Przeciwciała dwuswoiste przeciwko p95HER2 | |
| PL3512547T3 (pl) | Przeciwciała anty-pd-1 | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| ZA201807167B (en) | Humanized anti-il-1r3 antibodies | |
| GB201610044D0 (en) | Antibodies | |
| IL256579A (en) | Human antibodies | |
| GB201616699D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201603291D0 (en) | Antibodies | |
| PT3484921T (pt) | Anticorpos anti-il-22r | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
| IL260083B1 (en) | Antibody against myl9 | |
| HUE073389T2 (hu) | CD20 antitestek | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies |